Ignite Creation Date:
2025-12-25 @ 5:00 AM
Ignite Modification Date:
2026-01-26 @ 7:43 AM
Study NCT ID:
NCT00709618
Status:
TERMINATED
Last Update Posted:
2014-07-14
First Post:
2008-07-02
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
Sponsor:
GlaxoSmithKline
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
LPT111110
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None